Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
8.77
-0.05 (-0.57%)
At close: Mar 6, 2026, 4:00 PM EST
8.77
0.00 (0.00%)
After-hours: Mar 6, 2026, 4:00 PM EST
Karyopharm Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Karyopharm Therapeutics stock have an average target of 15.4, with a low estimate of 10 and a high estimate of 21. The average target predicts an increase of 75.60% from the current stock price of 8.77.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Karyopharm Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +71.04% | Feb 18, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Feb 5, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $30 → $19 | Buy | Maintains | $30 → $19 | +116.65% | Nov 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $15 | Hold → Strong Buy | Upgrades | $15 | +71.04% | Oct 13, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $15 → $12 | Buy | Reiterates | $15 → $12 | +36.83% | Oct 9, 2025 |
Financial Forecast
Revenue This Year
141.67M
from 146.07M
Decreased by -3.01%
Revenue Next Year
207.72M
from 141.67M
Increased by 46.62%
EPS This Year
-5.16
from -17.93
EPS Next Year
-4.48
from -5.16
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 165.7M | 364.5M | |||
| Avg | 141.7M | 207.7M | |||
| Low | 128.6M | 130.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 13.4% | 157.3% | |||
| Avg | -3.0% | 46.6% | |||
| Low | -12.0% | -8.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -3.21 | -2.64 | |||
| Avg | -5.16 | -4.48 | |||
| Low | -8.27 | -7.16 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.